Journal Info

Journal Info

副标题

For Authors

For Authors

副标题

For Reviewers

For Reviewers

副标题

2024, Vol. 28 ›› Issue (29): 4748-4756

Network meta-analysis on efficacy and safety of different biological agents in treatment of rheumatoid arthritis

Jia Hongsheng, Wang Fan, Chen Chun, Sun Bo, Fang Shengqi   

  1. Nanyang TCM Hospital, Nanyang 473000, Henan Province, China

  • Received:2023-11-07 Accepted:2023-12-21 Online:2024-10-18 Published:2024-03-23

  • Contact: Jia Hongsheng, Master, Nanyang TCM Hospital, Nanyang 473000, Henan Province, China

  • About author:Jia Hongsheng, Master, Nanyang TCM Hospital, Nanyang 473000, Henan Province, China

Abstract: OBJECTIVE: There are many kinds of biological agents for the treatment of rheumatoid arthritis in clinic, but the differences in therapeutic efficacy and safety are still unclear. The purpose of this study is to compare the differences in effectiveness and safety of different biological agents for the treatment of rheumatoid arthritis.
METHODS: CNKI, VIP, WanFang, China Biomedical Literature System, PubMed, Cochrane Library, Web of Science, and Embase databases were searched to collect the randomized controlled trials on biological agents for rheumatoid arthritis that meet the requirements from inception to October 1, 2022. The literature was selected by EndNote software, and the quality of the included literature was evaluated by RevMan 5.3 software. The software Stata 14.2 was used for direct meta-analysis and network meta-analysis of ACR20 (American College of Rheumatology 20% response), ACR50 (American College of Rheumatology 50% response), ACR70 (American College of Rheumatology 70% response), erythrocyte sedimentation rate, and adverse reactions.
RESULTS: Totally 39 articles were included, including 5 low-risk articles, 4 high-risk articles, and the remaining 30 articles contained unknown risk bias, with a total of 13 treatment measures. The results of network meta-analysis: (1) In ACR20, infliximab combined with methotrexate (OR=5.54, 95%CI: 1.33-23.01, P < 0.05), abatacept+methotrexate tablets (OR=3.21, 95%CI: 1.13-9.10, P < 0.05), and tocilizumab (OR=2.95, 95%CI: 1.61-5.44, P < 0.05) were better than methotrexate tablets. The probabilistic ranking of ACR20 was: infliximab+methotrexate tablets > abatacept+methotrexate tablets > tocilizumab > certlizumab > etanercept+methotrexate tablets. (2) In the aspect of ACR50, etanercept combined with methotrexate tablets (OR=4.04, 95%CI: 2.13-7.66, P < 0.05), infliximab combined with methotrexate tablets (OR=4.79, 95%CI: 1.19-19.26, P < 0.05), and tocilizumab combined with methotrexate tablets (OR=3.54, 95%CI: 1.36-9.22, P < 0.05) had better therapeutic effects than methotrexate tablets. The probabilistic ranking of ACR50 was: etanercept+methotrexate tablets > infliximab+methotrexate tablets > tocilizumab+methotrexate tablets > tocilizumab > certlizumab+methotrexate tablets. (3) In terms of ACR70, the therapeutic effects of infliximab combined with methotrexate tablets (OR=8.00, 95%CI: 2.31-27.69, P < 0.05), etanercept combined with methotrexate tablets (OR=4.26, 95%CI: 2.51-7.21, P < 0.05), and tocilizumab combined with methotrexate tablets (OR=3.51, 95%CI:1.82-6.80, P < 0.05) were better than methotrexate tablets. The probabilistic ranking of ACR70 was infliximab+methotrexate tablets > etanercept+methotrexate tablets > tocilizumab+methotrexate tablets > certlizumab > adalimumab+methotrexate tablets. (4) In erythrocyte sedimentation rate, etanercept combined with methotrexate tablets (SMD=-9.23, 95%CI: -16.55 to -1.92, P < 0.05) was better than etanercept and methotrexate tablets (SMD=14.59, 95%CI: 7.28-21.91, P < 0.05). The probabilistic ranking of erythrocyte sedimentation rate was etanercept+methotrexate tablets > infliximab+methotrexate tablets > etanercept > adalimumab+methotrexate tablets > methotrexate tablets. (5) In terms of adverse reactions, placebo (OR=0.62, 95%CI: 0.39-0.99, P < 0.05) was better than infliximab and certlizumab (OR=0.44, 95%CI: 0.25-0.78, P < 0.05). The probabilistic ranking of adverse reactions was placebo > infliximab > etanercept+methotrexate tablets > certlizumab > etanercept.
CONCLUSION: Based on evidence from 39 randomized controlled trials, infliximab combined with methotrexate tablets (highly recommended) can be the first choice in clinic, and etanercept combined with methotrexate tablets (highly recommended) can be the second choice in terms of good effectiveness and safety.

Key words: biological agent, rheumatoid arthritis, entanercept, infliximab, methotrexate tablets, tocilizumab, adalimumab, certlizumab, abatacept, network meta-analysis


分享到:

Publishing Information

Publishing House of Chinese Journal of Tissue Engineering Research


The Official Publication of

Chinese Association of Rehabilitation Medicine

Contact Us

General editorial enquiries:

Email: bwb01@crter.org

Copyright related contact:

Email: crter@crter.org

Commercial Sales contact (Reprints, advertising, etc.):

Email: bwb@crter.org